2023
Identification of blood protein biomarkers associated with prostate cancer risk using genetic prediction models: analysis of over 140,000 subjects
Zhong H, Zhu J, Liu S, Ghoneim D, Surendran P, Liu T, Fahle S, Butterworth A, Alam A, Deng H, Yu H, Wu C, Wu L. Identification of blood protein biomarkers associated with prostate cancer risk using genetic prediction models: analysis of over 140,000 subjects. Human Molecular Genetics 2023, 32: 3181-3193. PMID: 37622920, PMCID: PMC10630250, DOI: 10.1093/hmg/ddad139.Peer-Reviewed Original ResearchConceptsPCa riskProstate cancerHuge public health burdenEtiology of PCaBlood protein biomarkersConventional epidemiologic studiesProstate cancer riskPublic health burdenConventional observational studiesCancer Genome AtlasPCa patientsHealth burdenProtein biomarker candidatesObservational studyEpidemiologic studiesCancer riskTherapeutic strategiesCancer-related pathwaysSignificant associationBiomarker candidatesGenome AtlasProtein levelsDrug repurposingRiskPositive association
2008
Adipokine genes and prostate cancer risk
Moore SC, Leitzmann MF, Albanes D, Weinstein SJ, Snyder K, Virtamo J, Ahn J, Mayne ST, Yu H, Peters U, Gunter MJ. Adipokine genes and prostate cancer risk. International Journal Of Cancer 2008, 124: 869-876. PMID: 19035456, PMCID: PMC2879625, DOI: 10.1002/ijc.24043.Peer-Reviewed Original ResearchConceptsProstate cancer riskProstate cancerCancer riskOdds ratioIGF-1Prostate carcinogenesisADIPOQ geneBaseline blood drawCase-control studyAdipocyte-derived cytokineIGFBP-3Serum insulinLEP geneBlood drawFinnish menIntervention groupLarge cohortGG genotypeRelative oddsAdipokine genesAA genotypeCancerVariant allelesA alleleLogistic regression
2003
Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States)
Li L, Yu H, Schumacher F, Casey G, Witte J. Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes & Control 2003, 14: 721-726. PMID: 14674736, DOI: 10.1023/a:1026383824791.Peer-Reviewed Original ResearchConceptsIGFBP-3 molar ratioInsulin-like growth factorIGFBP-3Prostate cancerHigher IGFOdds ratioSibling-matched case-control studySerum insulin-like growth factorInsulin-like growth factor IProtein 3Growth factorIGFBP-3 associationSerum IGF levelsEffects of IGFConfidence intervalsImportant risk factorCase-control studyConditional logistic regressionGrowth factor IProstatic epithelial cellsAdvanced diseaseSerum IGFIGF levelsAggressive diseaseRisk factorsGenotype–phenotype analysis for the polymorphic CA repeat in the insulin-like growth factor-I (IGF-I) gene
Kato I, Eastham J, Li B, Smith M, Yu H. Genotype–phenotype analysis for the polymorphic CA repeat in the insulin-like growth factor-I (IGF-I) gene. European Journal Of Epidemiology 2003, 18: 203-209. PMID: 12800944, DOI: 10.1023/a:1023379100539.Peer-Reviewed Original ResearchConceptsPlasma IGF-I levelsIGF-I levelsInsulin-like growthPlasma IGFHospital-based case-control studyCase-control studyGenotype-phenotype analysisCA repeat lengthInverse associationOverall functional significanceProstate cancerStudy subjectsHealthy individualsChance findingWhite womenIGFRacial subgroupsDirect sequencingPositive associationCancerBlack menNumber of CaFunctional significanceAssociationPolymorphic CA
2001
Insulin-like growth factor-I and prostate cancer: a meta-analysis
Shi R, Berkel H, Yu H. Insulin-like growth factor-I and prostate cancer: a meta-analysis. British Journal Of Cancer 2001, 85: 991-996. PMID: 11592771, PMCID: PMC2375097, DOI: 10.1054/bjoc.2001.1961.Peer-Reviewed Original ResearchConceptsHedges's standardized mean differenceLevels of IGFProstate cancer patientsStandardized mean differenceIGFBP-3Prostate cancerHigher IGFCancer patientsInsulin-like growth factorIGF-binding proteinsEffects of IGFCase-control studyLow IGFMEDLINE searchIGFMean differenceGrowth factorCancerPatientsStandard protocolRiskLevelsLevels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence
Yu H, Nicar M, Shi R, Berkel H, Nam R, Trachtenberg J, Diamandis E. Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence. Urology 2001, 57: 471-475. PMID: 11248622, DOI: 10.1016/s0090-4295(00)01003-7.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCase-Control StudiesDisease ProgressionEnzyme-Linked Immunosorbent AssayHumansInsulin-Like Growth Factor Binding Protein 2Insulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm, ResidualProstate-Specific AntigenProstatic NeoplasmsConceptsPostoperative serum samplesInsulin-like growth factor IIGFBP-3IGFBP-2Growth factor IProstate cancerSerum levelsSerum samplesFactor IIGFBP-2 levelsIGFBP-3 levelsIGF-I levelsGroup of patientsLow serum levelsProstate cancer patientsProstate cancer recurrenceProtein 2Recurrent diseaseDisease recurrenceMedian timePrognostic valueCancer patientsRadical prostatectomyCancer recurrenceSerum collection
2000
DRAMATIC SUPPRESSION OF PLASMA AND URINARY PROSTATE SPECIFIC ANTIGEN AND HUMAN GLANDULAR KALLIKREIN BY ANTIANDROGENS IN MALE-TO-FEMALE TRANSSEXUALS
OBIEZU C, GILTAY E, MAGKLARA A, SCORILAS A, GOOREN L, YU H, DIAMANDIS E. DRAMATIC SUPPRESSION OF PLASMA AND URINARY PROSTATE SPECIFIC ANTIGEN AND HUMAN GLANDULAR KALLIKREIN BY ANTIANDROGENS IN MALE-TO-FEMALE TRANSSEXUALS. Journal Of Urology 2000, 163: 802. DOI: 10.1097/00005392-200003000-00023.Peer-Reviewed Original ResearchUrinary prostate specific antigenProstate-specific antigenCyproterone acetateHormonal therapySpecific antigenFemale transsexualsSensitive immunofluorometric procedureUrine samplesMonths of therapyMonths of treatmentInitiation of treatmentCyproterone acetate therapyProstate cancer treatmentHK2 concentrationsTransdermal estradiolAcetate therapyTumor burdenAntiandrogen treatmentSteroidal antiandrogenAndrogen receptorProstate cancerEthinyl estradiolStudy groupPatient's bloodTherapy successComparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy
Scorilas A, Yu H, Soosaipillai A, Gregorakis A, Diamandis E. Comparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy. Clinica Chimica Acta 2000, 292: 127-138. PMID: 10686282, DOI: 10.1016/s0009-8981(99)00211-9.Peer-Reviewed Original ResearchConceptsPercent free PSAProstate cancer patientsFree PSAProstate cancerCancer patientsRadical prostatectomyPercent free prostate-specific antigen levelsCancer aggressivenessFree prostate specific antigen levelsProstate-specific antigen levelProstate cancer screening programsAge-matched menCancer screening programsRecurrent prostate cancerBenign prostatic hyperplasiaProstate cancer aggressivenessAntigen levelsTotal PSAGleason scoreHealthy menProstatic hyperplasiaProstatic diseaseScreening programPatientsPathological indicatorsShorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer
Yu H, Bharaj B, Vassilikos E, Giai M, Diamandis E. Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer. Breast Cancer Research And Treatment 2000, 59: 153-161. PMID: 10817350, DOI: 10.1023/a:1006356502820.Peer-Reviewed Original ResearchConceptsBreast cancerAndrogen receptorAggressive formCAG repeatsPositive lymph nodesPrimary breast cancerRisk of deathAR transcriptional activityImpact of androgensPatients' overall survivalAction of androgensBreast cancer tissuesBreast cancer progressionAndrogen receptor geneLength of CAGLong CAG repeatsOverall survivalLymph nodesPathological variablesPatient survivalHistological gradeHomozygous womenProstate cancerMean CAGDisease featuresClinical implications of prostate-specific antigen in men and women.
Yu H. Clinical implications of prostate-specific antigen in men and women. Journal Of Gender-Specific Medicine 2000, 3: 45-8, 53. PMID: 11253246.Peer-Reviewed Original ResearchConceptsProstate-specific antigenPresence of PSAClinical implicationsLevels of PSABreast tissueBreast cancer patientsBreast cancer riskSex steroid hormonesValuable tumor markerExcess androgenFavorable prognosisPregnant womenBreast fluidCancer patientsNipple aspiratesProstate cancerClinical studiesCancer riskTumor markersCyst fluidFemale serumSteroid hormonesConcentration of PSAMore studiesWomen
1999
Prostate-specific antigen (PSA) in women.
Yu H, Berkel H. Prostate-specific antigen (PSA) in women. Journal Of The Louisiana State Medical Society 1999, 151: 209-13. PMID: 10234897.Peer-Reviewed Original ResearchConceptsProstate-specific antigenBreast cancerPSA levelsProduction of PSABetter disease-free survivalSerum prostate-specific antigenBreast tissueDisease-free survivalBreast cancer riskValuable tumor markerExcess androgenOverall survivalGestational agePregnant womenBreast fluidProgesterone receptorMenstrual cycleNipple aspiratesProstate cancerClinical studiesEstrogen receptorCancer riskTumor markersCyst fluidAmniotic fluid
1996
Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers.
Ferguson R, Yu H, Kalyvas M, Zammit S, Diamandis E. Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clinical Chemistry 1996, 42: 675-684. PMID: 8653891, DOI: 10.1093/clinchem/42.5.675.Peer-Reviewed Original ResearchConceptsTime-resolved immunofluorometric assayProstate-specific antigenL PSAPotential applicationsUltrasensitive time-resolved immunofluorometric assayUltrasensitive detectionPSA immunoreactivityImmunofluorometric assayWide dynamic rangeFree prostate-specific antigenPostradical prostatectomy patientsEstrogen receptor positivityUltrasensitive PSA assaysDynamic rangePSA changeReceptor positivityProstatectomy patientsProstate cancerBreast cancerPSA assaysHook effectLow analytical limitsSignificant associationMonoclonal antibodiesSerum samplesAssay of prostate-specific antigen from whole blood spotted on filter paper and application to prostate cancer screening.
Hoffman B, Yu H, Diamandis E. Assay of prostate-specific antigen from whole blood spotted on filter paper and application to prostate cancer screening. Clinical Chemistry 1996, 42: 536-544. PMID: 8605670, DOI: 10.1093/clinchem/42.4.536.Peer-Reviewed Original ResearchConceptsProstate-specific antigenProstate cancerOccult prostate cancerWhole bloodWhole blood concentrationsExtracts of bloodFilter paper procedureMicrograms/L.Cancer screeningPSA recoverySy/xBloodPlasma fractionConcentration of PSARegression analysisCancerAntigenCentralized laboratoriesMicroL of bufferMicroLFilter paperPaper discsHematocritRecoveryMonths
1995
Quantification of creatine kinase BB isoenzyme in tumor cytosols and serum with an ultrasensitive time-resolved immunofluorometric technique
Zarghami N, Yu H, Diamandis E, Sutherland D. Quantification of creatine kinase BB isoenzyme in tumor cytosols and serum with an ultrasensitive time-resolved immunofluorometric technique. Clinical Biochemistry 1995, 28: 243-253. PMID: 7554242, DOI: 10.1016/0009-9120(95)00010-7.Peer-Reviewed Original ResearchConceptsCK-BB levelsBreast tumor cytosolsCreatine kinase BBCK-BBProstate cancerTumor cytosolsCancer patientsEstrogen sensitivityHealthy subjectsSerum CK-BB levelsActive prostate cancerSensitive immunofluorometric procedurePost-radical prostatectomyProstate cancer patientsSerum CK-BBCK-BB isoenzymeSteroid hormone receptorsSerum PSAProgesterone receptorRadical prostatectomyBreast cancerMale volunteersHealthy volunteersPatientsBreast tumors